

## RECENT PUBLICATIONS

1. Silva R, Moran B, Das S, et al. Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report. *Case Rep Womens Health*. 2022;34:e00395.
2. Nolan K, O'Donnell K, Moloney FJ, Kelly CM, Potter S. The impact of a See and Treat Clinic on skin cancer treatment time. *Journal of Plastic, Reconstructive & Aesthetic Surgery*. 2022;75(2):893-939.
3. Lucas MW, Kelly CM. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. *Cancer Management and Research*. 2022;14:2493-2506.
4. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study☆. *Annals of Oncology*. 2022;33(5):534-543.
5. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. *Annals of Oncology*. 2022.
6. Galactionova K, Loibl S, Salari P, et al. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. *Frontiers in Oncology*. 2022;12.
7. Donohoe F, O'Meara Y, Roberts A, et al. Using menopausal hormone therapy after a cancer diagnosis in Ireland. *Irish Journal of Medical Science (1971 -)*. 2022.
8. Prior L, O'Dwyer R, Farooq AR, et al. Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study. *Breast Cancer Res Treat*. 2021.
9. Prior L, Featherstone H, O'Reilly D, et al. Competing mortality risks: predicted cardiovascular disease risk versus predicted risk of breast cancer mortality in patients receiving adjuvant chemotherapy in a single Irish center. *Cardiooncology*. 2021;7(1):8.
10. O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. *World J Clin Oncol*. 2021;12(3):164-182.
11. O'Reilly D, Carroll H, Lucas M, et al. Virtual oncology clinics during the COVID-19 pandemic. *Ir J Med Sci*. 2021.
12. McSorley LM, Tharmabala M, Al Rahbi F, et al. Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland. *Breast Cancer Res Treat*. 2021;188(3):789-798.
13. McSorley LM, Tharmabala M, Al Rahbi F, et al. Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland. *Breast Cancer Res Treat*. 2021.
14. Mallett V, Linehan A, Burke O, et al. A Multicenter Retrospective Review of Systemic Anti-Cancer Treatment and Palliative Care Provided to Solid Tumor Oncology Patients in the 12 Weeks Preceding Death in Ireland. *Am J Hosp Palliat Care*. 2021:1049909120985234.
15. Lynch SM, Russell NM, Barron S, et al. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. *Eur J Cancer*. 2021;152:78-89.
16. Loibl S, Marme F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. *J Clin Oncol*. 2021;39(14):1518-1530.

17. Keegan NM, Furney SJ, Walshe JM, et al. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER". *Cancers (Basel)*. 2021;13(6).
18. Giblin GT, Dennehy C, Featherstone H, et al. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy. *Circ Heart Fail*. 2021;14(2):e007524.
19. Donohoe F, O'Meara Y, Roberts A, et al. The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study. *Contemporary Clinical Trials Communications*. 2021;24:100865.
20. Chew SM, Lucas M, Brady M, Kelly CM. SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy. *BMJ Case Reports*. 2021;14(6):e238494.
21. Chew S, Carroll HK, Darwish WMZ, Higgins MJ, McCaffrey J, Kelly CM. Characterization of treatments and disease course for women with breast cancer brain metastases: Five-year retrospective single institution experience. *Journal of Clinical Oncology*. 2021;39(15\_suppl):e13055-e13055.
22. Chew S, Carroll HK, Darwish W, et al. Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience. *Cancer management and research*. 2021;13:8191-8198.
23. Bayani J, Poncet C, Crozier C, et al. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. *npj Breast Cancer*. 2021;7(1):98.
24. AISendi M, O'Reilly D, Zeidan YH, Kelly CM. Oligometastatic breast cancer: Are we there yet? *Int J Cancer*. 2021.
25. Montemurro F, Delalogue S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(). *Ann Oncol*. 2020;31(10):1350-1358.
26. Krop I, Abramson V, Colleoni M, et al. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. *Clin Cancer Res*. 2020;26(23):6149-6157.